IUK

PQShield selected to participate in AWS European Defence Accelerator

Retrieved on: 
Wednesday, July 12, 2023
NIST, Plexal point, Mentorship, Amazon Web Services, Confidentiality, Computer, Government, Government of the United Kingdom, Cryptography, Algorithm, IUK, CNI, AWS, APN, Risk management, Cryptocurrency

LONDON and OXFORD, England, July 12, 2023 /PRNewswire/ -- PQShield , a leading provider of quantum-safe cryptographic solutions, has been selected by AWS to participate in its AWS European Defence Accelerator, to advance the development and deployment of cutting-edge quantum-resistant encryption technology.

Key Points: 
  • LONDON and OXFORD, England, July 12, 2023 /PRNewswire/ -- PQShield , a leading provider of quantum-safe cryptographic solutions, has been selected by AWS to participate in its AWS European Defence Accelerator, to advance the development and deployment of cutting-edge quantum-resistant encryption technology.
  • This collaboration elevates PQShield's ability to support defense and national security organizations across Europe and addresses four key focus areas of the defense industry's needs identified by the AWS European Defence Accelerator.
  • Beginning in September 2023, the AWS European Defence Accelerator is a four-week technical, business, and mentorship program delivered in collaboration with Plexal, a United Kingdom Government supported innovation technology firm.
  • The AWS European Defence Accelerator provides an unprecedented opportunity to collaborate with multiple organizations simultaneously, driving innovation and reinforcing the security landscape.

PQShield selected to participate in AWS European Defence Accelerator

Retrieved on: 
Wednesday, July 12, 2023
NIST, Plexal point, Mentorship, Amazon Web Services, Confidentiality, Computer, Government, Government of the United Kingdom, Cryptography, Algorithm, IUK, CNI, AWS, APN, Risk management, Cryptocurrency

LONDON and OXFORD, England, July 12, 2023 /PRNewswire/ -- PQShield , a leading provider of quantum-safe cryptographic solutions, has been selected by AWS to participate in its AWS European Defence Accelerator, to advance the development and deployment of cutting-edge quantum-resistant encryption technology.

Key Points: 
  • LONDON and OXFORD, England, July 12, 2023 /PRNewswire/ -- PQShield , a leading provider of quantum-safe cryptographic solutions, has been selected by AWS to participate in its AWS European Defence Accelerator, to advance the development and deployment of cutting-edge quantum-resistant encryption technology.
  • This collaboration elevates PQShield's ability to support defense and national security organizations across Europe and addresses four key focus areas of the defense industry's needs identified by the AWS European Defence Accelerator.
  • Beginning in September 2023, the AWS European Defence Accelerator is a four-week technical, business, and mentorship program delivered in collaboration with Plexal, a United Kingdom Government supported innovation technology firm.
  • The AWS European Defence Accelerator provides an unprecedented opportunity to collaborate with multiple organizations simultaneously, driving innovation and reinforcing the security landscape.

Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

Retrieved on: 
Monday, November 28, 2022
Degenerative disease, MHC, Infection, UK Research and Innovation, Epitope, Public health, Innovation, Peptide, Laboratory, Allele, HLA, RNA, Cell, Developing country, IUK, Alphavirus, Department of Health and Social Care, Global health, Research, Medicine, Disease, UKRI, Government of the United Kingdom, Social work, CD8, Immortalised cell line, Human, DHSC, Organic acid, HLA-C, Vaccine, Pharmaceutical industry, Chikungunya, CHIKV

Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.

Key Points: 
  • Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
  • The library of CHIKV ligandome peptides identified by Emergex will now enter the next phase of development.
  • Laurens Rademacher, Chief Technology Officer at Emergex commented: The ligandome identified allows the addition of a Chikungunya vaccine candidate to Emergexs pipeline.
  • The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.